Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Francessca Glynn

Internal Medicine Midlothian, VA Medical Doctor

NPI 1063474690 CMS profile 3186

13700 St Francis Blvd, Suite 510, Midlothian, VA 23114

Open in the dashboard

General payments

$7,840

488 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Francessca Glynn of Midlothian, VA is reported in the CMS Open Payments database as having received $7,840 across 488 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $396 19
2024 General $362 16
2023 General $1,440 86
2022 General $2,024 128
2021 General $1,395 86
2020 General $941 63
2019 General $1,281 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Francessca Glynn
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Francessca Glynn were reported at $396. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Francessca Glynn Internal Medicine median Middle half National median
2019 $1,281 $159 $48–$570 $163
2020 $941 $119 $33–$402 $114
2021 $1,395 $135 $37–$521 $132
2022 $2,024 $141 $42–$496 $149
2023 $1,440 $149 $45–$519 $160
2024 $362 $154 $47–$537 $164
2025 $396 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $902 62 payments
  2. AstraZeneca Pharmaceuticals LP $638 30 payments
  3. Novo Nordisk Inc $636 45 payments
  4. Amgen Inc. $491 33 payments
  5. Lilly USA, LLC $490 31 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $368 22 payments
  7. Pfizer Inc. $304 20 payments
  8. GlaxoSmithKline, LLC. $296 28 payments
  9. Abbott Laboratories $273 12 payments
  10. Merck Sharp & Dohme Corporation $231 14 payments
  11. Other $3,210 191 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,834 487 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $514 31 payments
  2. Ozempic $397 26 payments
  3. RYBELSUS $335 21 payments
  4. JARDIANCE $309 19 payments
  5. EMGALITY $307 19 payments
  6. Repatha $303 20 payments
  7. TRELEGY ELLIPTA $252 25 payments
  8. BREZTRI $219 13 payments
  9. Cologuard Collection Kit $210 11 payments
  10. FARXIGA $210 8 payments
  11. Other $7,110 433 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 153 drugs

Part D claims

11,519

Median for Internal Medicine: 777

Drug cost

$840,757

Median for Internal Medicine: $73,373

Branded share of claims

20.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 66 $87,681
Ozempic Semaglutide Brand 74 $84,554
Eliquis Apixaban Brand 71 $73,764
Farxiga Dapagliflozin Propanediol Brand 45 $49,701
Xarelto Rivaroxaban Brand 40 $46,316
Breo Ellipta Fluticasone/Vilanterol Brand 46 $35,785
Myrbetriq Mirabegron Brand 59 $35,742
Synthroid Levothyroxine Sodium Brand 306 $29,518
Trulicity Dulaglutide Brand 23 $26,886
Januvia Sitagliptin Phosphate Brand 27 $26,752

The 10 drugs with the highest cost, of 153 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$162,709

Medicare's payments for the services billed

Medicare patients

660

Average age 75

Services billed

2,242

554 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 43%
Osteoporosis 20%
Depression 18%
Diabetes 17%
Cancer 16%
Ischemic heart disease 14%
Chronic kidney disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $15
$15 — —
ZAVZPRET
  • PFIZER INC. $15
$15 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $14
$14 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record